PXS - Great announcement putting the company in the spotlight for the future.
New strategic direction – to build a regional biotech centre of excellence in fibrosis and inflammation
o Multiple drugs from in‐house amine oxidase platform developed to phase 1 or 2
o Collaborate where necessary to de‐risk and accelerate internal and external programs
o Licence out to Big Pharma with attractive 1st in class drugs post phase 1 or 2
Short to mid‐term opportunities
o Milestone payments from Boehringer as PXS4728A progresses
o LOXL2 collaboration to phase 1 or 2 and subsequent partnering
o 3 additional drug programs in the drug discovery pipeline
o A stake in the US commercialisation of Bronchitol (funded by partner) and sales by distributors in the rest of the world
Financial strength
o Restructured Bronchitol business to reduce investment (>50%) and shorten time to profitability
o Pro forma March 31 2015 balance sheet cash at $62m
- Forums
- ASX - Day Trading
- Day Trading May 19 - Morning
Day Trading May 19 - Morning, page-11
-
- There are more pages in this discussion • 356 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)